Health Care & Life Sciences » Biotechnology | Five Prime Therapeutics Inc.

Five Prime Therapeutics Inc. | Mutual Funds

Mutual Funds that own Five Prime Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Growth Company Fund
1,441,079
4.05%
-7,819
0.04%
07/31/2018
SPDR S&P Biotech ETF
1,357,999
3.82%
3,495
0.33%
09/06/2018
BB Biotech AG
977,500
2.75%
200,000
0.33%
03/31/2018
Vanguard Total Stock Market Index Fund
815,883
2.29%
0
0%
07/31/2018
iShares Russell 2000 ETF
703,549
1.98%
-375
0.02%
09/06/2018
Fidelity Select Biotechnology Portfolio
651,600
1.83%
0
0.1%
07/31/2018
Fidelity Select Health Care Portfolio
600,000
1.69%
0
0.11%
07/31/2018
563,832
1.59%
35,650
0.36%
06/30/2018
Wellington Mgmt. Port (Dublin) Plc - Global Health Care Eq.
497,060
1.4%
180,060
0.32%
12/31/2017
Vanguard Extended Market Index Fund
465,273
1.31%
15,100
0.01%
07/31/2018

About Five Prime Therapeutics

View Profile
Address
111 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.fiveprime.com
Updated 07/08/2019
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.